Skip to main content

Table 2 Systemic treatment management patterns per HR/HER2 status

From: Epidemiological characteristics, clinical outcomes and management patterns of metastatic breast cancer patients in routine clinical care settings of Greece: Results from the EMERGE multicenter retrospective chart review study

  Overall HR+/HER2 HR+/HER2+ HR/HER2+ HR/HER2
Patients receiving first line treatment N = 374 N = 188 N = 56 N = 43 N = 46
n (%) n (%) n (%) n (%) n (%)
Taxanes & Antiangiogenic agents 54 (14.4) 35 (18.6) 4 (7.1) 1 (2.3) 6 (13.0)
Aromatase inhibitors only 41 (11.0) 36 (19.1) 2 (3.6) 1 (2.2)
Platinum compounds & Taxanes & Antiangiogenic agents 19 (5.1) 5 (2.7) 13 (28.3)
Taxanes & Anti-HER2 agents 18 (4.8) 1 (0.5) 11 (19.6) 6 (14.0)
Pyrimidine analogues & Anti-HER2 agents 15 (4.0) 2 (1.1) 4 (7.1) 9 (20.9)
Other chemotherapy & Anti-HER2 agents 9 (2.4) 3 (5.4) 6 (14.0)
Patients receiving second line treatment N = 254 N = 125 N = 36 N = 35 N = 33
n (%) n (%) n (%) n (%) n (%)
Aromatase inhibitors only 21 (8.3) 18 (14.4) 1 (2.8) 1 (3.0)
Anti-estrogens only 20 (7.9) 17 (13.6)
Aromatase inhibitors & mTOR inhibitors 20 (7.9) 17 (13.6) 2 (6.1)
Pyrimidine analogues & anti-HER2 agents 20 (7.9) 1 (0.8) 7 (19.4) 10 (28.6) 2 (6.1)
Anti-HER2 agents only 11 (4.3) 1 (0.8) 1 (2.8) 8 (22.9) 1 (3.0)
Other chemotherapy & Anti-HER2 agents 6 (2.4) 2 (5.6) 4 (11.4)
Platinum compounds & Pyrimidine analogues 6 (2.4) 1 (0.8) 4 (12.1)
Aromatase inhibitors & Anti-HER2 agents 6 (2.4) 6 (16.7)
Patients receiving third line treatment N = 175 N = 89 N = 28 N = 24 N = 18
n (%) n (%) n (%) n (%) n (%)
Taxanes only 15 (8.6) 12 (13.5) 1 (3.6) 1 (4.2) 1 (5.6)
Pyrimidine analogues & Anti-HER2 agents 13 (7.4) 4 (14.3) 8 (33.3) 1 (5.6)
Pyrimidine analogues only 11 (6.3) 10 (11.2) 1 (3.6)
Aromatase inhibitors only 11 (6.3) 10 (11.2)
Anthracyclines & Other chemotherapy 7 (4.0) 4 (4.5) 1 (4.2) 2 (11.1)
Other chemotherapy & Anti-HER2 agents 6 (3.4) 1 (1.1) 3 (10.7) 1 (4.2) 1 (5.6)
Pyrimidine analogues & Antiangiogenic agents 5 (2.9) 2 (2.2) 3 (16.7)
Anti-HER2 agents only 5 (2.9) 5 (20.8)
Patients receiving beyond the third line treatment N = 105 N = 49 N = 17 N = 18 N = 11
n (%) n (%) n (%) n (%) n (%)
Pyrimidine analogues only 6 (5.7) 5 (10.2) 1 (5.9)
Anti-estrogens only 5 (4.8) 5 (10.2)
Anthracyclines & Anti-HER2 agents 3 (2.9) 2 (11.1) 1 (9.1)
Other chemotherapy & Anti-HER2 agents 3 (2.9) 3 (16.7)
Pyrimidine analogues & Anti-HER2 agents 2 (1.9) 2 (11.1)
Pyrimidine analogues & Other chemotherapy & Anti-HER2 agents 2 (1.9) 2 (11.1)
Pyrimidine analogues & Taxanes & Other chemotherapy 2 (1.9) 2 (18.2)
  1. Only systemic treatment patterns utilized in at least 10.0% of one or more of the four subpopulations per HR/HER2 status are shown. Taxanes (docetaxel, paclitaxel, nab-paclitaxel); platinum compounds (carboplatin, cisplatin); pyrimidine analogues (capecitabine, fluorouracil, gemcitabine); anthracyclines (doxorubicin, liposomal and pegylated doxorubicin, epirubicin); aromatase inhibitors (anastrozole, exemestane, letrozole); anti-estrogens (tamoxifen, fulvestrant); other chemotherapy (cyclophosphamide, eribulin, methotrexate, vinorelbine); anti-HER2 agents (trastuzumab, lapatinib); antiangiogenic agents (bevacizumab, sorafenib), mTOR inhibitor (everolimus). N, number of patients analyzed for each outcome; n, number of patients who received the particular treatment